Drug Name: RNS60
Company: Revalesio Corporation
Location: US-Washington
Website: http://www.revalesio.com
Drug Type: Oxygenated Nanobubbles
Conditions: ALS
Mechanism Type: Immunomodulation, Neuroprotection
Mechanism: RNS60 is a 0.9% saline solution containing oxygenated nanobubbles that is generated by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow under elevated oxygen pressure. RNS60, according to studies of a SOD1 mouse model of ALS, may help promote the survival of neurons by activating the PI3K-Akt pathway. The approach may also help reduce inflammation by multiple mechanisms including: increasing CD4+/FoxP3+ regulatory T cells and stimulating the production of anti-inflammatory cytokines.
U.S. Status for ALS: Phase II

[1] ALS Association and ALS Finding a Cure® Supported Phase II RNS60 Trial is Now Enrolling ALS Association, ClinicalTrials.gov, 19 Sep 2017. Accessed 14 Feb 2018 from https://alsadotorg.wordpress.com/2017/09/19/clinical-trial-als-association-supported-phase-ii-rns60-trial-is-now-enrolling/.
[2] Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis. ClinicalTrials.gov, 30 Dec 2015. Accessed 11 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT02525471.
[3] A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS). Chandra, G et al. J Neuroimmune Pharmacol. 2017 Nov 29. doi: 10.1007/s11481-017-9771-4.
[4] Increase in Mitochondrial Biogenesis in Neuronal Cells by RNS60, a Physically-Modified Saline, via Phosphatidylinositol 3-Kinase-Mediated Upregulation of PGC1╬▒. Modi KK, Jana A, Ghosh S, Watson R, Pahan K. PLoS One. 2014;9(8):e103606.
[5] RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue. Vallarola, A. et al, J Neuroinflammation. 2018 Mar 1;15(1):65.

Last updated February 14th, 2018

Share this: